The United Kingdom and the United States have concluded a major bilateral deal that will maintain no import taxes on British medicine exports being sold in the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise funding on pharmaceuticals through the public health system. This commitment secures that duties on these key exports will remain at zero for a timeframe of the next three years.
This deal is in response to recent threats to significantly raise import taxes on patented pharmaceutical products, with increases mentioned as high as double the cost.
"This agreement between the Britain reinforces the worldwide climate for new treatments and brings long-overdue equity to transatlantic drug exports," an announcement said.
Economic Significance
Drugs are one of the UK's largest goods shipped to the America, which is easily the largest buyer for leading companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months to the end of September, the UK exported drugs totaling over eleven billion pounds to the US. This amount made up 17.4% of British export trade in that span.
"This agreement protects employment, stimulates funding and facilitates the UK to establish itself as a international leader for life sciences," a government official commented.
Specific UK Commitments
The pact entails several notable pledges from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum manufacturers must refund to the NHS to control costs will be limited at fifteen percent. In the past, rebates exceeded 20%.
Industry Background
The deal takes place against a long-running row between the sector and the British authorities over medicine costs and NHS adoption.
The disagreement were intensified by claims that US consumers were paying a premium for the identical medicines than patients in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure acknowledged that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
